Geoffrey von Maltzahn, Flagship General Partner and co-founder & CEO of Flagship-founded Tessera Therapeutics, explains Tessera's novel gene writing bioplatform and its vast potential for preventing and curing disease.
More from:
Human Health,
Sustainability
Three Questions with Hari Pujar, Founding President of Mirai Bio and Flagship Operating Partner
Pioneering a Sustainable Future for Food
The Next Generation of Biologics Are Supranatural
Three Questions with Volker Herrmann, Flagship CEO-Partner & CEO of Sonata Therapeutics
Pioneering Profile
Q&A with Molly Gibson on Leading Company Origination
Letter of Support
